Bioclimatic modelling in the holocene and in future warming scenarios in Arbutus unedo L.

Growing forests wildfires in Portugal are an increasing concern since forests in the Mediterranean region are vulnerable to recent global warming. Long-term negative effects are expected on the vegetation with the coming increasing drought. The strawberry tree (Arbutus unedo L.) displays potential to be a successfully business-like cultured in several regions of Portugal and southern Europe, as it is well adapted to climate and soils. In Portugal, this species has been used by local populations particularly for spirit production and for fruit consumption, although it has different possible commercial uses, from processed and fresh fruit production to ornamental, pharmaceutical and chemical applications. In addition, due to its pioneer status, it is valuable for land recovery and desertification avoidance, besides being fire resistant. The available strawberry tree’s data is presence-only. For modelling purposes, a set of placements within the landscape of interest (Portugal) was applied. The species, observed in 318 plots, together with a vector of environmental covariates (7 bioclimatic attributes, slope and altitude) and a defined background were used for modeling purposes. Maxent 3.4.1 was the used software, where the estimated quantity is the probability of the presence of the species, conditioned on the environment. Maxent uses the environmental covariate data from the occurrence records and the background sample, to estimate the ratio between the conditional density of the covariates at the presence sites and the marginal (i.e., unconditional) density of covariates across the study area and so, estimating the relative suitability of one place vs. another. Three different climate scenarios (control run; 2050 and 2070) were tested for two emission scenarios (RCP 4.5 and RCP 8.5, WorldClim), besides the past, 6,000 BP (Mid-Holocene). The reduction of habitat suitable for this species is very significant in the southern regions, even for the best warming scenario (RCP 4.5) in 2050. Central and Northern mountain regions are predicted refuge for this species. Forest policies and management should consider the impact of climate change on the usable areas for forestry, seeing a case-study species particularly adapted to the Mediterranean regions and wildfires, such as strawberry tree. The distribution of the species in the Middle Holocene agrees with previous genetic and fossils studies in the region, which supported two putative refuges for the species since the Last Glacial Maximum and a cryptic refugia in the East-Central mountain region.info:eu-repo/semantics/publishedVersio

Treatment of chronic hepatitis C with recombinant human interferon-alpha 2a: results of a randomized controlled clinical trial

Sixty consecutive patients with chronic hepatitis C were included in a randomized controlled trial of recombinant human interferon-alpha 2a vs. no treatment. Treated patients received tapering doses of interferon thrice weekly for 1 yr. Twenty treated cases (66.7%) normalized serum aminotransferase levels within the first 4 mo of treatment, but reactivation or breakthrough frequently occurred afterward (20% in both cases). Only one of the untreated patients showed spontaneous normalization of serum aminotransferase levels. Liver histology did not improve in patients without a biochemical response or with breakthrough during therapy, whereas it did not worsen in long-term responders and reactivating patients. Lack of response does not appear to be related to serum interferon antibodies, although their early appearance is more frequent in patients who showed reactivation later on. No biochemical parameter was found to be predictive for positive response to treatment. Antibody to c100 became negative in 62.5% of long-term responders, whereas no change was recorded in other treated patients or controls. Reactivation and breakthrough often occur during treatment, and further studies are needed to determine the most effective schedule (dose and time) of interferon treatment. Loss of c100 antibody during therapy may be a marker of long-term maintenance of response to interferon therapy

Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study

inhibitor danusertib hydrochloride (PHA-739358) in breast (BC), ovarian (OC), pancreatic (PC), colorectal (CRC), small-cell (SCLC) and non-small-cell lung (NSCLC) cancers. METHODS: Consenting adult patients with good performance and organ function with advanced/metastatic tumours who had failed systemic therapy were treated in independent, disease-specific cohorts with danusertib 500 mg/m(2) given as 24-h i.v. infusion every 14 days with until progression or unacceptable toxicity. A two-stage design was applied. Primary end point was the progression-free rate (PFR) at 4 months (RECIST1.1). RESULTS: A total of 223 patients were enrolled with 219 actively treated. The median relative dose intensity of danusertib was similar for all tumour types (84.6%-99.6%). The median number of biweekly treatment cycles ranged from 3 to 4/patient (maximum 5-40 cycles/entity) and the median treatment duration varied between 7.6 and 10.0 weeks per histotype. Danusertib did not meet pre-specified protocol criteria for clinically relevant activity in any of the treated cancers. The PFR at 4 months was 18.4% in BC, 12.1% in OC, 10.0% in PC, 10.4% in NSCLC (all histotypes), 16.1% in squamous NSCLC and 0% in SCLC and CRC. Some radiological and/or biochemical indication of antitumor activity was seen in BC, OC, PC and NSCLC, including two confirmed partial responses. The most frequent drug-related non-laboratory adverse events (AEs) were fatigue/asthenia, nausea, diarrhoea, anorexia, vomiting, alopecia, constipation and pyrexia. Common laboratory AEs included haematological toxicity, hypalbuminaemia and increases in liver enzymes. Treatment was discontinued due to AEs in only 5.5% of patients. Plasma concentrations of danusertib were in line with results from earlier studies. CONCLUSION: Single-agent danusertib did show only marginal anti-tumour activity in common solid tumours after failure of prior systemic therapies. The safety and PK profile was consistent with previous experience

Tilmen Hoyuk, una capitale di 4000 anni fa

Resoconto delle ricerche archeologiche a Tilmen Hoyu